Gujarat Themis Biosyn Ltd.
NSE: GUJTHEM BSE: GUJTHEM
Prev Close
389.65
Open Price
390.9
Volume
58,924
Today Low / High
384.55 / 398
52 WK Low / High
208 / 479
Range
371 - 410
Prev Close
389.75
Open Price
394.9
Volume
8,278
Today Low / High
385 / 398.25
52 WK Low / High
192.35 / 479.45
Range
377 - 417
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 390 (target range: 371 - 410), reflecting a change of 0.35 (0.0898242%). On the BSE, it is listed at 397 (target range: 377 - 417), showing a change of 7.25 (1.86017%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Gujarat Themis Biosyn Ltd. Graph
Gujarat Themis Biosyn Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gujarat Themis Biosyn Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 390.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 397.00 | 400.97 | 360.87 - 441.07 |
| 404.94 | 323.95 - 485.93 | ||
| 408.91 | 286.24 - 531.58 | ||
| Bearish Scenario | 397.00 | 393.03 | 353.73 - 432.33 |
| 389.06 | 311.25 - 466.87 | ||
| 385.09 | 269.56 - 500.62 |
Overview of Gujarat Themis Biosyn Ltd.
ISIN
INE942C01045
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
197,987
Market Cap
42,496,453,350
Last Dividend
0.67
Official Website
IPO Date
2025-02-25
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of GUJTHEM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-04 | September 04, 25 | 0.67 | 0.67 | 2025-09-05 | 2025-10-12 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 150.79 Cr | 31.88 Cr | 118.91 Cr | 0.7886 | 3.44 Cr | 2.35 Cr | 64.25 Cr | 48.77 Cr | 4.48 | 71.42 Cr | 0.3234 |
| 2024-03-31 | 169.81 Cr | 41.61 Cr | 128.20 Cr | 0.7550 | 3.90 Cr | 1.45 Cr | 75.55 Cr | 59.16 Cr | 5.43 | 83.54 Cr | 0.3484 |
| 2023-03-31 | 148.13 Cr | 30.78 Cr | 117.35 Cr | 0.7922 | 2.93 Cr | 1.44 Cr | 72.51 Cr | 57.97 Cr | 5.32 | 80.14 Cr | 0.3913 |
| 2022-03-31 | 114.19 Cr | 20.89 Cr | 93.30 Cr | 0.8170 | 0.45 Cr | 0.83 Cr | 56.57 Cr | 43.62 Cr | 4.00 | 62.00 Cr | 0.3820 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 42.35 Cr | 7.44 Cr | 34.91 Cr | 0.8244 | 17.98 Cr | 14.26 Cr | 1.31 | 21.76 Cr | 0.3368 |
| 2025-06-30 | 35.87 Cr | 8.00 Cr | 27.88 Cr | 0.7771 | 11.89 Cr | 9.06 Cr | 0.83 | 14.20 Cr | 0.2526 |
| 2025-03-31 | 37.72 Cr | 8.35 Cr | 29.37 Cr | 0.7787 | 15.59 Cr | 12.00 Cr | 0.00 | 17.26 Cr | 0.3180 |
| 2024-12-31 | 39.52 Cr | 8.86 Cr | 30.66 Cr | 0.7758 | 17.30 Cr | 12.97 Cr | 1.19 | 19.11 Cr | 0.3282 |
| 2024-09-30 | 34.72 Cr | 6.88 Cr | 27.83 Cr | 0.8018 | 13.96 Cr | 10.57 Cr | 0.97 | 15.71 Cr | 0.3044 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 6.36 Cr | 4.03 Cr | 10.38 Cr | 35.15 Cr | 7.21 Cr | 54.80 Cr | 294.29 Cr | 376.67 Cr | 112.24 Cr |
| 2025-03-31 | 11.69 Cr | 1.85 Cr | 11.69 Cr | 31.45 Cr | 5.05 Cr | 51.97 Cr | 246.50 Cr | 301.31 Cr | 52.93 Cr |
| 2024-09-30 | 8.38 Cr | 9.73 Cr | 18.11 Cr | 28.57 Cr | 4.64 Cr | 52.25 Cr | 178.61 Cr | 248.15 Cr | 24.72 Cr |
| 2024-03-31 | 6.47 Cr | 7.66 Cr | 14.13 Cr | 27.59 Cr | 3.33 Cr | 47.56 Cr | 136.64 Cr | 221.11 Cr | 19.74 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,794.20 | ₹4,304,886,803,174.00 | ₹1,442,249.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,426.50 | ₹1,706,033,829,370.00 | ₹128,633.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,791.50 | ₹1,283,215,885,760.00 | ₹168,916.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,279.30 | ₹1,065,033,273,233.00 | ₹981,114.00 |
| Lupin Limited | LUPIN | ₹2,112.00 | ₹964,681,344,000.00 | ₹573,967.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹927.45 | ₹933,231,714,026.00 | ₹435,235.00 |
| Mankind Pharma Limited | MANKIND | ₹2,178.80 | ₹899,419,690,874.00 | ₹1,107,712.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,195.10 | ₹694,116,019,647.00 | ₹670,100.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,631.00 | ₹673,270,515,000.00 | ₹35,892.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,968.10 | ₹555,399,412,193.00 | ₹359,544.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,012.30 | ₹546,496,817,959.00 | ₹1,243,204.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,465.90 | ₹371,905,013,166.00 | ₹98,690.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,659.80 | ₹332,303,772,715.00 | ₹81,623.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,798.00 | ₹281,653,104,000.00 | ₹111,646.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,438.60 | ₹272,707,988,894.00 | ₹177,392.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,155.00 | ₹228,875,000,000.00 | ₹2,254.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,341.20 | ₹217,934,497,063.00 | ₹421,135.00 |
| Eris Lifesciences Limited | ERIS | ₹1,572.20 | ₹214,160,196,030.00 | ₹92,545.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,096.00 | ₹206,509,893,344.00 | ₹42,086.00 |
| Cohance Lifesciences Limited | COHANCE | ₹535.80 | ₹204,979,473,612.00 | ₹515,022.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹876.90 | ₹172,366,203,436.00 | ₹49,903.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,086.00 | ₹172,129,300,410.00 | ₹80,321.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹905.05 | ₹162,103,387,844.00 | ₹1,393,984.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,963.90 | ₹149,279,369,774.00 | ₹37,297.00 |
| Granules India Limited | GRANULES | ₹574.50 | ₹139,413,177,342.00 | ₹1,264,501.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹888.65 | ₹109,020,779,900.00 | ₹55,174.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,577.50 | ₹92,583,053,105.00 | ₹4,240.00 |
| Strides Pharma Science Limited | STAR | ₹882.55 | ₹81,347,028,741.00 | ₹94,112.00 |
| FDC Limited | FDC | ₹418.90 | ₹68,201,144,188.00 | ₹69,872.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹740.45 | ₹67,119,788,842.00 | ₹119,729.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹331.75 | ₹64,884,267,458.00 | ₹619,024.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹423.05 | ₹64,769,825,637.00 | ₹167,280.00 |
| Sequent Scientific Limited | SEQUENT | ₹209.68 | ₹52,383,058,368.00 | ₹957,574.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹137.08 | ₹44,485,419,283.00 | ₹1,212,051.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹849.95 | ₹43,108,703,295.00 | ₹33,260.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹390.00 | ₹42,496,453,350.00 | ₹58,924.00 |
| Innova Captab Limited | INNOVACAP | ₹721.40 | ₹41,282,063,781.00 | ₹31,617.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,316.40 | ₹38,310,974,346.00 | ₹5,767.00 |
| Suven Life Sciences Limited | SUVEN | ₹170.65 | ₹37,612,286,460.00 | ₹133,676.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹393.35 | ₹35,901,054,500.00 | ₹120,462.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹348.20 | ₹34,918,368,589.00 | ₹39,213.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹456.00 | ₹32,105,022,000.00 | ₹3,257.00 |
| Hikal Limited | HIKAL | ₹252.71 | ₹31,159,332,533.00 | ₹526,032.00 |
Key Executives
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1954
Gender: Not Specified
Year Born: 1975
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Gujarat Themis Biosyn Ltd.
The CEO is Sachin Dinesh Patel.
The current price is ₹390.00.
The range is ₹208-479.
The market capitalization is ₹4,249.65 crores.
The dividend yield is 0.17%.
The P/E ratio is 87.93.
The company operates in the Healthcare sector.
Overview of Gujarat Themis Biosyn Ltd. (ISIN: INE942C01045) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,249.65 crores and an average daily volume of 197,987 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.67.